Eric Lefkofsky, Founder and CEO of Tempus, shared on LinkedIn:
”Congratulations to Moderna and Merck on today’s positive Phase 3 results for INTerpath-001, a major milestone for melanoma treatment and the future of more personalized care.
We are proud to partner with Moderna and Merck in support of this important program, sequencing patients as it advances, and we’re excited to see this work continue for the benefit of patients.”
Eric Lefkofsky was recognized among OncoDaily’s The 100 Most Influential People in Oncology in 2025, highlighting his contributions to the field of oncology.
Nominations for 100 Influential People in Oncology 2026 are now open, recognizing leaders, researchers, clinicians, innovators, advocates, and other individuals making a meaningful impact on oncology and cancer care.
Don’t miss the opportunity to nominate yourself, a colleague, or someone whose contributions deserve to be recognized.
Submit your nomination by September 15: 100 Influential People in Oncology 2026 – Nominations are Open!
Moderna and Merck Announce Positive Phase 3 INTerpath-001 Results in Melanoma
